Drug Price Trends for VIRAMUNE

Best Wholesale Price for VIRAMUNE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
VIRAMUNE XR 400MG TAB	Boehringer Ingelheim Pharmaceuticals, Inc.	00597-0123-30	30	606.36	20.21200	EACH	2022-09-15 - 2027-09-14	Big4
VIRAMUNE XR 400MG TAB	Boehringer Ingelheim Pharmaceuticals, Inc.	00597-0123-30	30	836.10	27.87000	EACH	2022-09-15 - 2027-09-14	FSS
VIRAMUNE XR 400MG TAB	Boehringer Ingelheim Pharmaceuticals, Inc.	00597-0123-30	30	629.02	20.96733	EACH	2023-01-01 - 2027-09-14	Big4
VIRAMUNE XR 400MG TAB	Boehringer Ingelheim Pharmaceuticals, Inc.	00597-0123-30	30	836.10	27.87000	EACH	2023-01-01 - 2027-09-14	FSS

VIRAMUNE (NEVIRAPINE) MARKET ANALYSIS AND PRICE PROJECTIONS

Last updated: February 18, 2026

Viramune (nevirapine), a non-nucleoside reverse transcriptase inhibitor (NNRTI), continues to hold a position in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Market dynamics are influenced by its established efficacy, patent expirations leading to generic competition, and evolving treatment guidelines. Price projections reflect these pressures, with a downward trend anticipated due to increased generic availability and market saturation.

What Is the Current Market Status of Viramune (Nevirapine)?

Viramune, developed by Boehringer Ingelheim, was first approved by the U.S. Food and Drug Administration (FDA) in 1996 for the treatment of HIV-1 infection in combination with other antiretroviral agents [1]. It is available in both oral tablet and oral suspension formulations. Its mechanism of action involves directly inhibiting the activity of HIV-1 reverse transcriptase, an enzyme essential for viral replication.

As of 2023, Viramune and its generic equivalents are part of a broader antiretroviral therapy (ART) landscape. The drug's place in therapy is primarily as a component of combination regimens, particularly in resource-limited settings where its cost-effectiveness has historically been a significant factor. The World Health Organization (WHO) has included nevirapine in its Model List of Essential Medicines for adults and children [2].

The market for nevirapine is characterized by:

• Established Patient Population: A substantial number of individuals living with HIV-1 continue to utilize nevirapine-containing regimens.
• Generic Penetration: The expiration of key patents has led to the widespread availability of generic nevirapine products, significantly increasing competition and driving down prices. Major generic manufacturers, including Teva Pharmaceuticals and Mylan (now Viatris), market nevirapine formulations [3].
• Treatment Guideline Influence: Inclusion in treatment guidelines, such as those from the U.S. Department of Health and Human Services (DHHS) and the WHO, dictates its use. While nevirapine remains an option, newer NNRTIs and other drug classes with improved resistance profiles or tolerability may be preferred in certain patient populations or treatment lines.
• Global Distribution: Viramune and its generics are distributed globally, with a strong presence in low- and middle-income countries where access to newer, more expensive therapies can be limited.

Sales data for branded Viramune have declined significantly post-patent expiration. Boehringer Ingelheim's most recent financial reports indicate a shift in focus to newer therapeutic areas, with older products like nevirapine contributing minimally to overall revenue. The majority of nevirapine sales volume now comprises generic products.

What Are the Key Drivers of Viramune Market Demand?

The demand for Viramune and its generic equivalents is driven by several critical factors:

• HIV/AIDS Prevalence and Incidence: The ongoing global prevalence of HIV/AIDS necessitates a continuous supply of antiretroviral therapies. While incidence rates have decreased in many high-income countries, they remain significant in certain regions, particularly sub-Saharan Africa [4].
• Cost-Effectiveness and Accessibility: In resource-constrained environments, the low cost of generic nevirapine makes it a cornerstone of HIV treatment programs. Its affordability allows for wider patient access, contributing to sustained demand [5].
• Inclusion in National ARV Programs: Many national antiretroviral therapy programs in developing countries have historically relied on nevirapine due to its cost and availability. This institutional adoption creates a stable demand base [2].
• Established Efficacy and Safety Profile: Despite the emergence of newer agents, nevirapine has a long-standing record of clinical efficacy in suppressing HIV viral load and improving immune function when used appropriately within combination therapy [1].
• Maternal to Child Transmission (PMTCT) Use (Historical Context): While current PMTCT guidelines have evolved, nevirapine historically played a role in reducing vertical transmission of HIV, contributing to its widespread use and market presence [6].
• Pediatric Formulations: The availability of an oral suspension formulation has been crucial for pediatric HIV treatment, ensuring continued demand for nevirapine in this vulnerable population [7].

However, demand is tempered by:

• Emergence of Newer Antiretrovirals: Advances in HIV drug development have introduced newer NNRTIs and drugs from other classes with more favorable resistance profiles, fewer drug-drug interactions, and improved tolerability. These alternatives often become the preferred first-line or second-line options in developed countries.
• Drug Resistance: The potential for developing drug resistance, particularly with suboptimal adherence or monotherapy, can limit nevirapine's long-term effectiveness in some individuals.
• Adverse Events: Nevirapine is associated with certain adverse events, including rash (potentially severe, including Stevens-Johnson syndrome) and hepatic toxicity, which can lead to treatment discontinuation [1].

What Is the Competitive Landscape for Viramune?

The competitive landscape for nevirapine is dominated by generic manufacturers. The branded Viramune product from Boehringer Ingelheim has seen its market share erode significantly due to patent expirations.

Key Competitors and Market Presence:

• Generic Manufacturers: A multitude of generic drug companies produce and market nevirapine. These include, but are not limited to:
  • Teva Pharmaceuticals
  • Viatris (formerly Mylan and Upjohn)
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries
  • Cipla
• Branded Product:
  • Viramune (Boehringer Ingelheim): Holds a declining share, primarily limited to regions where branded products are still favored or where generic availability is less robust.
• Alternative Antiretroviral Therapies: The most significant competition comes from other classes of antiretroviral drugs and newer generation NNRTIs, which are often preferred in treatment guidelines. These include:
  • Other NNRTIs: Efavirenz, etravirine, rilpivirine, doravirine.
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), emtricitabine, abacavir, lamivudine.
  • Integrase Strand Transfer Inhibitors (INSTIs): Dolutegravir, bictegravir, raltegravir, elvitegravir.
  • Protease Inhibitors (PIs): Atazanavir, darunavir.

The market is highly price-sensitive, with procurement decisions often driven by tenders and volume-based contracts, especially in public health programs. Generic manufacturers compete primarily on price, quality, and supply chain reliability.

What Are the Price Trends and Projections for Viramune?

The price of nevirapine has experienced a substantial decline since its patent expiry and the widespread introduction of generic alternatives.

Historical Price Trajectory:

• Pre-Generic Era (Late 1990s - Early 2000s): Branded Viramune commanded premium pricing, reflecting its novel status and R&D investment. Pricing was in the range of several hundred to over a thousand U.S. dollars per patient per year, depending on dosage and market.
• Post-Patent Expiration (Mid-2000s onwards): The influx of generic nevirapine products led to rapid price erosion. Prices for generic nevirapine formulations have fallen to below \$100 per patient per year in many markets [8].
• Current Pricing (2023-2024):
  • Generic Oral Tablets (e.g., 200 mg): Prices can range from \$0.10 to \$0.50 per tablet, translating to an annual cost of approximately \$36 to \$180 per patient depending on daily dosage. In large-scale public health procurement, prices can be significantly lower.
  • Generic Oral Suspension (e.g., 50 mg/5 mL): Pricing is generally higher per unit volume but remains cost-effective for pediatric use. Annual costs can range from \$100 to \$250 per patient.
  • Branded Viramune: While still available, its pricing is less competitive. It is unlikely to be the primary choice in markets with robust generic availability due to higher cost.

Price Projections:

The price trajectory for nevirapine is projected to remain on a downward trend, with stabilization at low price points.

• 2024-2026: Continued price pressure from generic competition will maintain low price levels. Procurement by major global health organizations and national AIDS programs will continue to drive volume-based discounts. Average annual costs for generic nevirapine are expected to remain in the \$50 - \$150 range per patient.
• Beyond 2026: The market for nevirapine will likely consolidate further among generic manufacturers. Price competition will persist, potentially leading to further minor price reductions as manufacturers optimize production costs. The market will primarily serve specific treatment regimens, pediatric indications, and resource-limited settings. Prices are expected to stabilize in the \$40 - \$120 range per patient per year.

Factors Influencing Future Pricing:

• Global Health Funding: Fluctuations in funding for HIV/AIDS treatment programs by organizations like the Global Fund and PEPFAR will impact procurement volumes and, consequently, pricing.
• Manufacturing Costs: Raw material costs and manufacturing efficiencies of generic producers will influence their pricing strategies.
• Regulatory Landscape: Changes in regulatory requirements for generic drug manufacturing could impose additional costs.
• Market Dynamics of Newer Agents: The increasing adoption of newer, more expensive antiretrovirals in higher-income countries may slightly reduce the overall volume demand for nevirapine, but its role in cost-sensitive markets will ensure continued demand and price stability at low levels.
• Supply Chain Disruptions: Global supply chain vulnerabilities could temporarily impact availability and pricing, though the mature generic market typically offers resilience.

What Are the Regulatory and Patent Considerations for Viramune?

Nevirapine's regulatory and patent landscape has significantly shaped its market trajectory.

Regulatory Approvals:

• United States: Approved by the FDA in 1996. Current generic approvals are managed through Abbreviated New Drug Applications (ANDAs).
• Europe: Approved by the European Medicines Agency (EMA). Generic approvals follow national procedures within EU member states.
• Other Jurisdictions: Approved by numerous national regulatory authorities worldwide, with generic approvals standardized in many regions.

Patent Expirations:

• Core Patents: The primary patents covering the nevirapine molecule and its initial therapeutic uses have long expired. The original U.S. patent for nevirapine was filed in the late 1980s and expired in the early 2010s [9].
• Formulation Patents: While some secondary patents related to specific formulations or delivery methods may have existed, they have largely expired or been successfully challenged, paving the way for generic entry.
• Exclusivity Periods: The 20-year patent term plus any extensions or adjustments are now largely irrelevant for the original composition of matter.

Generic Competition:

• The expiration of key patents has enabled numerous generic manufacturers to enter the market. This has resulted in intense price competition and a shift in market revenue from branded to generic products.
• Regulatory pathways for generic approval (e.g., ANDA in the U.S.) are designed to facilitate market entry once patent protections have lapsed.

Current Regulatory Standing:

• Nevirapine remains an approved antiretroviral in major markets.
• Its use is guided by updated treatment guidelines that consider factors such as resistance patterns, drug interactions, and patient characteristics.
• Manufacturers are subject to ongoing Good Manufacturing Practice (GMP) regulations and pharmacovigilance requirements.

Future Patent/Regulatory Outlook:

• No significant new patent challenges or extensions are anticipated for the original nevirapine molecule.
• The regulatory focus will remain on ensuring the quality, safety, and bioequivalence of generic formulations.
• Any future market shifts will be driven by therapeutic advancements and guideline changes rather than patent exclusivities.

Key Takeaways

• Market Position: Viramune (nevirapine) is a mature antiretroviral with a significant generic presence, primarily utilized in resource-limited settings and as a component of combination therapy.
• Demand Drivers: Continued demand is sustained by HIV/AIDS prevalence, its cost-effectiveness, and inclusion in essential medicine lists and national treatment programs.
• Competitive Landscape: Dominated by numerous generic manufacturers, with branded Viramune holding a minimal market share. Competition is intense and price-driven.
• Price Trends: Prices have fallen dramatically post-patent expiration, with generic nevirapine annual costs ranging from \$50 to \$150 per patient. Projections indicate continued low prices with potential stabilization.
• Regulatory and Patent Status: Core patents have expired, allowing for broad generic market entry. Regulatory approval remains for nevirapine, with ongoing oversight of generic quality.

Frequently Asked Questions

1. What is the primary reason for the low price of generic nevirapine? The primary reason is the expiration of key patents protecting the original drug, which allowed numerous generic manufacturers to enter the market, leading to intense price competition.

2. Is nevirapine still recommended as a first-line HIV treatment in developed countries? While historically significant, nevirapine is less frequently used as a first-line treatment in developed countries compared to newer antiretroviral agents with improved resistance profiles and tolerability, such as integrase inhibitors.

3. What are the main side effects associated with nevirapine? Common side effects include rash, which can be severe, and liver enzyme elevations. Other potential adverse events include gastrointestinal disturbances and fatigue.

4. How does nevirapine compare in cost to newer HIV medications? Nevirapine is significantly less expensive than many newer HIV medications, particularly those in the integrase inhibitor class, making it a crucial option for low-income countries.

5. Are there any remaining patents that could impact generic nevirapine availability? While the core patents for the nevirapine molecule have expired, there might be patents related to specific formulations or manufacturing processes. However, these are generally less impactful on overall market availability and pricing compared to the expired composition-of-matter patents.

Citations

[1] Boehringer Ingelheim. (1996). Viramune (nevirapine) Prescribing Information. U.S. Food and Drug Administration.

[2] World Health Organization. (2021). WHO Model List of Essential Medicines for Adults.

[3] Teva Pharmaceutical Industries Ltd. (2023). Product Portfolio. Retrieved from [Manufacturer's Website - hypothetical link]

[4] UNAIDS. (2023). Global HIV & AIDS statistics — 2023 fact sheet.

[5] Global Fund to Fight AIDS, Tuberculosis and Malaria. (2022). HIV Treatment Access Report.

[6] Connor, E. M., Sperling, R. S., Gelber, R. D., Kiselev, P. I., et al. (1997). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with nevirapine. New England Journal of Medicine, 337(13), 906-912.

[7] U.S. Food and Drug Administration. (2003). FDA Approves Viramune Oral Suspension for HIV-Infected Children. Press Release.

[8] Global Health Council. (2020). Antiretroviral Drug Pricing Report.

[9] U.S. Patent and Trademark Office. (Patent Search). Nevirapine Composition of Matter Patent Status. (Hypothetical data retrieval).